Current Trials
Find out more about taking part in one of our trials
Now Recruiting
IMPACT Study
Trial of a new medication in people with 1 diabetes aged 12-45. Screening visit to be conducted within 9 weeks of diagnosis.
PROTECT Study
The PROTECT Study is testing how well an investigational medicine works in children and adolescents with Type 1 diabetes (T1D).
Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD)
ITAD is a multicentre, randomised, double-blind, placebo-controlled clinical trial of to see if a drug called aldesleukin, can preserve insulin production in children and young adults recently diagnosed with type 1 diabetes.
Ustekinumab in adolescents with new onset type 1 diabetes
Recruitment paused
Trial of a new medication in 12-18 year olds with Type 1 diabetes within 100 days of diagnosis
Research study for people with Type 1 Diabetes: EXALT
Recruitment closed
The main purpose of this study is to assess the safety of three different doses of an investigational drug in patients who have been recently diagnosed with type 1 diabetes.
The Effect of Abatacept on the Immune System in Type 1 Diabetes
Recruitment closed
This study aims to gain a better understanding of the immune processes that lead to the destruction of insulin producing beta cells.
The Effect of Anti-IL-21 and Liraglutide in Newly Diagnosed Type 1 Diabetes
Recruitment closed
This study will investigate if a new drug Anti-IL-21 when given together with another drug marketed for type 2 diabetes called liraglutide can preserve the beta cells in subjects diagnosed with type 1 diabetes.
Join our research and help change the future of Type 1 Diabetes
Twitter Feeds
This is another solid brick in the wall of novel therapies for Type 1 Diabetes. A massive #ThankYou to People with #T1D who take part in #clinicaltrials and support the advancement of #Immunotherapy for #T1D.
@IM_Therapeutics @JDRF @JDRFUK @DiabetesUK @DiabetesUKCymru @britsocimm https://twitter.com/IM_Therapeutics/status/1417820295189180418